ADMIN | STUDY | CLOSE DATE |
Intergroup Study |
OPEN | COOPGRP | COUNT |
---|---|---|---|---|---|---|
S2015- | E | SWOG | 6 | |||
sum | 6 | |||||
BREAST | S1706-Breast, Inflammatory, RT +/- Olaparib | Y | ALLIANCE | 10 | ||
CCTG | 6 | |||||
ECOG-ACRIN | 5 | |||||
NRG | 34 | |||||
SWOG | 49 | |||||
sum | 104 | |||||
S2007-Breast, Brain Mets, Sacituzumab Govitecan | Y | ALLIANCE | 4 | |||
ECOG-ACRIN | 1 | |||||
SWOG | 6 | |||||
sum | 11 | |||||
CCD | S1703-Met Breast, STM-monitoring v Usual Care | Y | ALLIANCE | 4 | ||
ECOG-ACRIN | 16 | |||||
NRG | 14 | |||||
SWOG | 194 | |||||
sum | 228 | |||||
S1912CD-CREDIT, Fin Counseling to reduce Fin Hardship | Y | ALLIANCE | 4 | |||
ECOG-ACRIN | 1 | |||||
SWOG | 25 | |||||
sum | 30 | |||||
ERLYTX | S1609-Rare Tumor, Comb Nivo/Ipi | Y | ALLIANCE | 105 | ||
ECOG-ACRIN | 78 | |||||
NRG | 137 | |||||
SWOG | 473 | |||||
sum | 793 | |||||
S2012-Small Cell NEC, Stg IV, Combo Chemo +/- Atezo | Y | ALLIANCE | 1 | |||
sum | 1 | |||||
GI | S1613-mCRC, Adv/Met, TP vs CETIRI | 31-MAR-22 | N | ALLIANCE | 6 | |
ECOG-ACRIN | 4 | |||||
NRG | 5 | |||||
SWOG | 39 | |||||
sum | 54 | |||||
S1922-Small Bowel,Ram+Pac vs FOLFIRI, mets/unresect | Y | ALLIANCE | 7 | |||
ECOG-ACRIN | 1 | |||||
NRG | 2 | |||||
SWOG | 11 | |||||
sum | 21 | |||||
S2001-Rando II, Mets Pancreas , BRCA1/2, Comb Chemo | Y | ALLIANCE | 2 | |||
ECOG-ACRIN | 2 | |||||
NRG | 1 | |||||
SWOG | 10 | |||||
sum | 15 | |||||
S2104-Panc,Resect High-risk,Postop Adj Chemo vs Obs | Y | NRG | 2 | |||
SWOG | 2 | |||||
sum | 4 | |||||
GU | S1802-Pros, Stg IV, SST +/- Surg/RT to Primary Tum | Y | ALLIANCE | 81 | ||
ECOG-ACRIN | 56 | |||||
NRG | 66 | |||||
SWOG | 362 | |||||
sum | 565 | |||||
S1806-Blad, MIBC, ChemoRT +/- Atezolizumab | Y | ALLIANCE | 18 | |||
ECOG-ACRIN | 27 | |||||
NRG | 86 | |||||
SWOG | 163 | |||||
sum | 294 | |||||
S1931-RENAL, Stg IV, IO + Nephrectomy. vs IO Only | Y | ALLIANCE | 2 | |||
ECOG-ACRIN | 1 | |||||
NRG | 1 | |||||
SWOG | 29 | |||||
sum | 33 | |||||
S1937-Blad, Mets, Eribulin +/- Gem vs SOC | Y | NRG | 1 | |||
SWOG | 9 | |||||
sum | 10 | |||||
LEUK | S1712-CML, Chronic Phase, TKI +/- Ruxolitinib | Y | ALLIANCE | 11 | ||
ECOG-ACRIN | 6 | |||||
NRG | 2 | |||||
SWOG | 57 | |||||
sum | 76 | |||||
S1905-T-ALL/T-LBL, Rel/Ref, OBI-3424 | Y | ALLIANCE | 2 | |||
SWOG | 8 | |||||
sum | 10 | |||||
S1925-CLL/SLL, Newly Dx HR, Early vs Delayed V+O | Y | ALLIANCE | 4 | |||
ECOG-ACRIN | 4 | |||||
SWOG | 19 | |||||
sum | 27 | |||||
LUNG | LUNGMAP-NSCLC, Adv, Master | Y | ALLIANCE | 622 | ||
ECOG-ACRIN | 298 | |||||
NRG | 316 | |||||
SWOG | 1331 | |||||
sum | 2567 | |||||
S1701-Thymic Adv, Carbo/Pac/Ram vs. Carbo/Pac | Y | ALLIANCE | 3 | |||
ECOG-ACRIN | 2 | |||||
SWOG | 13 | |||||
sum | 18 | |||||
S1800D-Non-Match: N-803 + Pembro vs SoC | Y | ALLIANCE | 3 | |||
ECOG-ACRIN | 3 | |||||
NRG | 1 | |||||
SWOG | 18 | |||||
sum | 25 | |||||
S1827-SCLC, MRI Surveillance +/- PCI | Y | ALLIANCE | 11 | |||
CCTG | 11 | |||||
ECOG-ACRIN | 2 | |||||
NRG | 42 | |||||
SWOG | 36 | |||||
sum | 102 | |||||
S1900E-KRAS G12C: Sotorasib (AMG 510) | Y | ALLIANCE | 13 | |||
ECOG-ACRIN | 11 | |||||
NRG | 4 | |||||
SWOG | 38 | |||||
sum | 66 | |||||
S1914-NSCLC, High Risk Early Stg, SBRT +/- Atezo | Y | ALLIANCE | 5 | |||
ECOG-ACRIN | 9 | |||||
NRG | 13 | |||||
SWOG | 81 | |||||
sum | 108 | |||||
S1929-ESCLC, SLFN11+, Atezolizumab ± Talazoparib | Y | ALLIANCE | 7 | |||
ECOG-ACRIN | 7 | |||||
NRG | 5 | |||||
SWOG | 64 | |||||
sum | 83 | |||||
S1933-NSCLC, Stg II-III, RT + Atezo | Y | ALLIANCE | 2 | |||
NRG | 1 | |||||
SWOG | 20 | |||||
sum | 23 | |||||
LYMPH | S1608-FL, TGR-1202/Lenalidomide/CHOP or Benda +Ob | T | ALLIANCE | 15 | ||
ECOG-ACRIN | 5 | |||||
NRG | 11 | |||||
SWOG | 41 | |||||
sum | 72 | |||||
S1826-HD, Adv, Age 12+, N+AVD vs BV+AVD | Y | ALLIANCE | 119 | |||
CCTG | 21 | |||||
COG | 288 | |||||
ECOG-ACRIN | 77 | |||||
NRG | 44 | |||||
SWOG | 345 | |||||
sum | 894 | |||||
S1918-DLBCL, Adv, Age 75+, CC-486 +/- R-miniCHOP | Y | ALLIANCE | 18 | |||
ECOG-ACRIN | 5 | |||||
NRG | 2 | |||||
SWOG | 10 | |||||
sum | 35 | |||||
MELAN | S1801-Melan, Adv, Adj vs Neoadj Pembrolizumab | 05-MAY-22 | N | ALLIANCE | 32 | |
ECOG-ACRIN | 50 | |||||
NRG | 47 | |||||
SWOG | 216 | |||||
sum | 345 | |||||
S2000-MELAN, M1d/ BRAF, Enco+Bini+Nivo vs Ipil+Nivo | Y | ALLIANCE | 1 | |||
ECOG-ACRIN | 3 | |||||
NRG | 1 | |||||
SWOG | 7 | |||||
sum | 12 | |||||
MMYEL | S1803-MM, Maintenance, Len vs Len/Dara | Y | ALLIANCE | 139 | ||
ECOG-ACRIN | 117 | |||||
NRG | 72 | |||||
SWOG | 473 | |||||
sum | 801 | |||||
S2005-WM, Prev. Untreated, I/R +/- Venetoclax | Y | ECOG-ACRIN | 1 | |||
sum | 1 | |||||
PEOLC | S1820-Rectal, Diet modification to manage GI sx | 27-APR-22 | N | ALLIANCE | 4 | |
ECOG-ACRIN | 1 | |||||
NRG | 29 | |||||
SWOG | 61 | |||||
sum | 95 | |||||
PREV | S0820-PACES: ColrecStg0-3 Blind DFMO/Sulindac | Y | ALLIANCE | 36 | ||
ECOG-ACRIN | 30 | |||||
NRG | 38 | |||||
SWOG | 235 | |||||
sum | 339 | |||||
S1823-GCT, Obs. Cohort, miRNA371 | Y | ALLIANCE | 61 | |||
CCTG | 90 | |||||
ECOG-ACRIN | 39 | |||||
NRG | 25 | |||||
SWOG | 313 | |||||
sum | 528 | |||||
S1904-Breast, Decision making for chemoprevention | Y | ALLIANCE | 44 | |||
ECOG-ACRIN | 21 | |||||
NRG | 37 | |||||
SWOG | 81 | |||||
sum | 183 | |||||
SURV | S1501-Surv, Breast Stg IV, Card Tox w/ Carvedilol | Y | ECOG-ACRIN | 34 | ||
SWOG | 199 | |||||
S1501 | Y | ALLIANCE | 20 | |||
NRG | 20 | |||||
sum | 273 | |||||
SXQOL | S1600-Bladder,Radical Cystectomy Outcomes Nutrition | Y | ALLIANCE | 5 | ||
NRG | 1 | |||||
SWOG | 134 | |||||
sum | 140 | |||||
S1614-HBV in Ca Pts, anti-HBV therapy vs SOC | Y | NRG | 1 | |||
SWOG | 3 | |||||
sum | 4 | |||||
S2013-I-CHECKIT: ICI toxicity risk prediction study | Y | ALLIANCE | 39 | |||
ECOG-ACRIN | 24 | |||||
NRG | 28 | |||||
SWOG | 218 | |||||
sum | 309 | |||||